Game-changing pan-TEAD inhibitor for solid tumours
Drug Target Review
JUNE 12, 2023
Leveraging AI-guided structure-based drug design, Insilico’s research and development team generated an impressive portfolio of over 6,000 molecules and identified three highly promising hit series. He is an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Let's personalize your content